

James R. Condo (#005867)  
Amanda C. Sheridan (#027360)  
SNELL & WILMER L.L.P.  
One Arizona Center  
400 E. Van Buren, Suite 1900  
Phoenix, Arizona 85004-2202  
Telephone: 602.382.6000  
Facsimile: 602.382.6070  
jcondo@swlaw.com  
asheridan@swlaw.com

Richard B. North, Jr. (admitted *pro hac vice*)  
Georgia Bar No. 545599  
Matthew B. Lerner (admitted *pro hac vice*)  
Georgia Bar No. 446986  
NELSON MULLINS RILEY & SCARBOROUGH LLP  
201 17th Street, NW / Suite 1700  
Atlanta, GA 30363  
Telephone: (404) 322-6000  
Telephone: (404) 322-6050  
richard.north@nelsonmullins.com  
matthew.lerner@nelsonmullins.com

*Attorneys for Defendants*  
*C. R. Bard, Inc. and*  
*Bard Peripheral Vascular, Inc.*

**IN THE UNITED STATES DISTRICT COURT**  
**FOR THE DISTRICT OF ARIZONA**

IN RE: Bard IVC Filters Products Liability  
Litigation

No. 2:15-MD-02641-DGC

**DEFENDANTS C. R. BARD, INC.  
AND BARD PERIPHERAL  
VASCULAR, INC.'S REPLY IN  
SUPPORT OF THEIR MOTION TO  
EXCLUDE THE OPINIONS OF  
DAVID GARCIA, M.D. AND  
MICHAEL STREIFF, M.D.**

(Assigned to the Honorable David G.  
Campbell)

**(Oral Argument Requested)**

## INTRODUCTION

Bard moved to exclude three specific categories of opinions from Drs. Garcia and Streiff (collectively the “Doctors”): (1) their “opinions” parroting Dr. Kessler’s opinions; (2) their opinions regarding physician expectations and corporate conduct; and, (3) Dr. Garcia’s case-specific opinions for Plaintiff Doris Jones. Plaintiffs, however, muddy the waters and argue issues not originally raised in Bard’s motion.<sup>1</sup>

## ARGUMENT

### **A. Plaintiffs Concede That Regurgitating Dr. Kessler’s Opinions is Impermissible.**

Plaintiffs concede in their Omnibus Statement that an expert can only rely on another expert’s opinion “as long as the expert does not [1] merely act as a conduit for the other expert’s opinion and [2] provided that the record shows that the expert independently evaluated the evidence supporting the other expert’s opinion.” (Dkt. No. 7799 at 7 (citing *In re Toyota Motor Corp. Unintended Acceleration Mktg., Sales Practices, & Prods. Liab. Litig.*, 978 F. Supp. 2d 1053 (C.D. Cal. 2013))). Plaintiffs argue that the Doctors meet these two requirements, but do not address the numerous testimony citations in Bard’s motion to the contrary.<sup>2</sup> The Doctors’ testimony and expert report Addendum make clear that they are serving as simple conduits for Dr. Kessler’s opinions, and that the Doctors have done no independent evaluation of the documents underlying Dr. Kessler’s report.

First, for example, Plaintiffs accuse Bard of “an exaggerated mischaracterization” by asserting that the Doctors “regurgitated” Dr. Kessler’s report. (Dkt. No. 7808 at 8.) Yet this is precisely what Dr. Garcia admitted to:

---

<sup>1</sup> Plaintiffs filed a separate Omnibus Statement Of Law And Generally-Applicable Arguments In Opposition To Bard’s Motions To Exclude Plaintiffs’ Experts Under Rule 702 And *Daubert* (Doc. 7799). Plaintiffs’ Omnibus Statement is not directed at any specific *Daubert* motion Bard filed. As such, Bard does not respond to the Omnibus Statement but instead will address any necessary issues in the context of its individual *Daubert* replies.

<sup>2</sup> However, Plaintiffs omit citing the second prong in their Opposition brief, and only superficially address this requirement as discussed below.

1  
2 Q. So in drafting your addendum and kind of essentially  
3 regurgitating what Dr. Kessler found in his report, did  
4 you attempt to be as accurate as possible in describing  
5 Dr. Kessler's findings?

6 A. I did.

7 (Mot. Ex. D, Garcia Dep., at 210:1-5.). Dr. Streiff also unequivocally testified that the  
8 Doctors did not modify Dr. Kessler's findings in any way, *i.e.*, they are serving as a mere  
9 conduit for Dr. Kessler's opinions:

10 Q. Okay. But you didn't modify Dr. Kessler's findings in  
11 any, any way?

12 A. I don't think so, no.

13 Q. You didn't change any of his findings in the process of  
14 taking what you saw from his report and inserting it  
15 into your report?

16 A. I don't – I don't think so. No, I don't recall doing that.

17 Q. So you included seven numbered paragraphs in your  
18 report, you addendum repeating what Dr. Kessler  
19 himself said in his own report?

20 A. Right.

21 (Mot. Ex. C, Streiff Dep., at 303:8-19.)

22 Also, Plaintiffs argue that Dr. Kessler's report only provided the Doctors with  
23 factual background and confirmed what they independently researched. (Pl. Br. at 8.) The  
24 Addendum itself belies this assertion. It goes beyond mere factual background by opining  
25 that Bard misled the FDA, and what Bard should and should not have done as a  
26 reasonable manufacturer. And, it paraphrases Dr. Kessler's opinions on pre-market  
27 regulatory submissions, and engineering and testing data far outside the practice of  
28 medicine, let alone the specialty of hematology, and paraphrases topics that the Doctors  
did not independently research:

- Bard mislead [sic] the FDA on the tendency of the Recovery filter to migrate...They represented to others and used an inappropriate minimum safety threshold and performance specification in their stability/migration in vitro studies..." (Mot. Ex. A, Rep., at p. 8, ¶ 1.)

- 1 • In light of these test results...Bard should not have marketed the filter since its  
2 performance was significantly poorer than the comparator, was not performing  
3 as intended, expected and represented prior to marketing and failed safety  
4 thresholds for migration... (*Id.* at ¶ 3.)
- 5 • Dr. Kessler also noted that perforation, filter fracture and tilting were  
6 significantly more common with the RNF than the SNF. Internal documents  
7 quoted in Dr. Kessler's report confirm that Bard knew of these deficiencies  
8 with the RNF but continued to market the device...In experimental testing [the  
9 G2] failed to meet the pre-specified standard of resistance to migration of  
10 greater than or equal to the SNF, so Bard changed and lowered the performance  
11 standard..." (*Id.* at p. 9, ¶ 5.)

12 Second, regarding the additional requirement of independent evaluation of the  
13 underlying facts, the extent of Plaintiffs' argument is, without citing the record, that the  
14 Doctors' "evaluation of the documents supporting the opinions of Drs. Kessler [sic]  
15 satisfies any reliability concerns the Court may have..." (Pl. Br. at 9.) However, the  
16 Doctors testified that they only reviewed *two* out of Dr. Kessler's more than 500  
17 underlying documents: a medical article by Dr. Asch, and Dr. Betensky's expert report,  
18 which the Doctors also did not independently evaluate. (Mot. Ex. D, Garcia Dep. 212:8 –  
19 213:6.) The Doctors admitted that they did not even *review* the underlying data, let alone  
20 evaluate it. Dr. Garcia was unequivocal:

21 Q. Did you independently review and assess the reliability  
22 of the underlying data that Dr. Kessler relied on?

23 A. Not beyond what I just told you [referring to the Asch  
24 article and Betensky report].

25 Q. Okay. Did you check or test any of the assumptions that  
26 Dr. Kessler made about the data that he analyzed?

27 A. No.

28 Q. Did you verify the documents that Dr. Kessler reviewed  
actually show what he says they show?

A. Not beyond what I just told you.

(*Id.*) Similarly, even if Dr. Streiff wanted to review the underlying documents, he did not  
have access to them:

Q. You never actually pulled [the] underlying documents?

A. True.

1 Q. Okay. Did you independently assess the reliability of  
2 the underlying data that Dr. Kessler relied on?

3 A. I couldn't do that.

4 \*\*\*

5 Q. Okay. Did you verify the documents that Dr. Kessler  
6 reviewed actually showed what he says they showed?

7 A. I – Again, I, I saw, read the report. I don't have the, the  
8 documents it was based on.

9 (Mot. Ex. C, Streiff Dep., 307:22 – 308:20.) In other words, the *only* document that the  
10 Doctors properly verified is the Asch article, a published version of the Recovery Filter  
11 clinical study. That one document cannot support any of the opinions copied from Dr.  
12 Kessler's report which include all the topics covered by Dr. Kessler, including regulatory  
disclosures and internal design, testing, and risk assessments.

13 And, in any event, the Doctors do not have the expertise to reliably verify Dr.  
14 Kessler's findings. The Doctors have no regulatory experience and are not familiar with  
15 the types of documents that Dr. Kessler relied upon to form his opinions or his methods.  
16 (Mot. Ex. C, Streiff Dep. 98:13 – 101:24; Mot. Ex. D, Garcia Dep. 83:16 – 85:12.) (*See*  
17 *also*, July 12, 2017, Deposition of Michael Streiff, at 277:10 – 278:17, attached as Exhibit  
18 A (testifying that he is not basing these opinions “on any particular regulation, standard,  
19 or law” and that they are “[a]ll personal opinions based on reading the Kessler report.”))  
20 As a result, the Doctors are not qualified to evaluate Dr. Kessler's opinions, and did not  
21 apply any reliable methodology or relevant experience to evaluating Dr. Kessler's  
22 regulatory opinions. These opinions should be excluded because the Doctors are merely a  
23 conduit for Dr. Kessler's opinions, and the Doctors did not independently evaluate the  
24 underlying data.

25 **B. The Court Should Exclude Opinions On Physician Expectations and**  
26 **Corporate Conduct.**

27 The Doctors' physician expectations opinions fall into two categories. First, that  
28 “manufacturers, like Bard, [should] continuously apprise the clinicians who order and

1 implant IVC filters about their safety profile, performance characteristics, design  
2 problems, and internal risk assessments.” (Pl. Br. at 4 (citing the Doctors’ expert report).)  
3 In other words, Plaintiffs’ argue that the Doctors should be able to opine that reasonable  
4 physicians expect to be told about the content of Dr. Kessler’s report. Second, the Doctors  
5 opine that “questions remain as to whether [IVC filters generally] are effective, but  
6 concede that IVC filters should be implanted in patients with “acute venous  
7 thromboembolism with a contraindication to anticoagulation.” (Mot. Ex. A, Rep., at p. 6.)  
8 In other words, Plaintiffs argue that the Doctors should be able to opine that reasonable  
9 physicians expect to be warned that filters are overprescribed.

10 **1. The Doctors’ Lack Qualifications For Their “Continuous**  
11 **Appraisal” Opinion, And Do Not Use Reliable Methodology.**

12 Plaintiffs argue that the Doctors can opine on physician expectations for “clinicians  
13 who order and implant IVC filters” because this is a variation of the medical standard of  
14 care. Plaintiffs offer no legal basis for extending a reasonable physician standard, which is  
15 a required *element* of a medical malpractice claim, to a products liability claim in which  
16 the manufacturer’s conduct, not the physician’s, is at issue. The only authority relied on  
17 by Plaintiffs for such an expansion is *Saint Alphonsus Med. Ctr. - Nampa, Inc. v. St.*  
18 *Luke's Health Sys., Ltd.*, No. 1:12-CV-00560-BLW, 2014 WL 407446 (D. Idaho Jan. 24,  
19 2014). But, *Saint Alphonsus* was an antitrust case addressing whether all physicians  
20 needed access to a shared electronic medical record system, and has nothing to do with the  
21 issues at hand.<sup>3</sup> And, even if this did somehow relate to a medical standard of care,  
22 Plaintiffs did not address the fact that neither of the Doctors “order [or] implant IVC  
23 filters.” (Mot. 5-6.)

24  
25  
26 <sup>3</sup> Plaintiffs also cite *Primiano v. Cook*, 598 F.3d 558, 567 (9th Cir. 2010) for the generic  
27 proposition that an expert’s opinion may be admitted when the expert adequately  
28 explained how he based his opinions on his experience, and used “the ordinary  
methodology of evidence-based medicine” to develop his opinion. This is also  
inapplicable to the Doctors’ specific opinions, particularly because they opine that Bard  
should have disclosed internal company documents.

1 Second, and most critically, Plaintiffs argue against a straw man of whether  
 2 physician expectations regarding the use of Bard's filters is relevant. Bard argued a totally  
 3 different issue: that, under the guise of "physician expectations," the Doctors intend to  
 4 offer a corporate conduct opinion that Bard withheld information from physicians and the  
 5 FDA based solely on their review of Dr. Kessler's report. This information, based on  
 6 documents such as confidential regulatory filings as part of the 510(k) process, internal  
 7 emails and memoranda, draft bench testing documents, draft PowerPoint presentations,  
 8 and other documents that physicians never review or rely on, are never publicly disclosed  
 9 by any manufacturer. In other words, the Doctors intend to opine on matters wholly  
 10 unrelated to the plain meaning of "physician expectations" and far outside the scope of  
 11 their expertise. Indeed, Plaintiffs concede that the Doctors "used Dr. Kessler's opinions to  
 12 further demonstrate not only that evidence of IVC filters' efficacy does not exist, but that  
 13 Bard was aware of this fact." (Pl. Br. at 9.)

14 Courts in this circuit have held that "it is insufficient for an expert to simply rely on  
 15 or parrot another expert's report prepared solely for litigation." *Crescenta Valley Water*  
 16 *Dist. v. Exxon Mobile Corp.*, No. CV 07-2630-JST (ANX), 2013 WL 12120533, at \*2  
 17 (C.D. Cal. Mar. 14, 2013). "Moreover, more scrutiny will be given to an expert's reliance  
 18 on the information or analysis of another expert where the other expert opinions were  
 19 developed for the purpose of litigation." *In re Toyota Motor Corp. Unintended*  
 20 *Acceleration Mktg., Sales Practices, & Prod. Liab. Litig.*, 978 F. Supp. 2d 1053, 1066  
 21 (C.D. Cal. 2013).

22 Tracking the opinions contained in Dr. Kessler's report, the Doctors state that "it is  
 23 critically important that manufacturers of IVC filters continuously apprise the clinicians  
 24 who order and implant IVC filters about their safety profile, performance characteristics,  
 25 design problems, and internal risk assessments." (Mot. Ex. A, Rep., at pp. 6-7.) Plaintiffs  
 26 argue that this is based on the Doctors' clinical experience, even though these categories  
 27 of information are non-clinical. Moreover, the Doctors testified that this statement,  
 28 referring to internal testing and quality assurance documents, was based solely on their



1 *personal* opinions after reading Dr. Kessler’s report. (Ex. A, Streiff Dep., at 277:10 –  
 2 278:17 (testifying that he is not basing these opinions “on any particular regulation,  
 3 standard, or law” and that they are “[a]ll personal opinions based on reading the Kessler  
 4 report.”)); (Mot. Ex. C, Streiff Dep. 274:23 – 277:5 (testifying that “that’s not from  
 5 literature. That’s from Dr. Kessler’s report”); Mot. Ex. D, Garcia Dep. 193:6-9 (testifying  
 6 “this is a statement that could apply to the manufacturer of any device or medication that’s  
 7 going to be prescribed or deployed by a treating physician”).) In other words, the Doctors’  
 8 opinion is that Bard should have disclosed what Dr. Kessler says Bard should have  
 9 disclosed to physicians. For the same reasons that the Doctors cannot be a conduit for Dr.  
 10 Kessler’s opinions, such as failing to independently evaluate Dr. Kessler’s opinions, this  
 11 “physician expectations” opinion should be excluded.

## 12 **2. The Doctors’ General IVC Filter Efficacy Opinion Lacks** 13 **Relevance And Is Unhelpful to the Jury.**

14 The Doctors also state under the “Physician Expectations” section of their report  
 15 that “questions remain as to whether [IVC filters generally] are effective.” (Mot. Ex. A,  
 16 Rep., at pp. 6.) Bard agrees that in the proper context, evidence regarding the efficacy of  
 17 IVC filters generally would be admissible. But, Plaintiffs argue a different issue: that Bard  
 18 should have warned physicians regarding an alleged lack of efficacy of all IVC filters. (Pl.  
 19 Br. at 9.) Plaintiffs do not explain how this opinion, which has nothing to do with  
 20 physicians’ expectations regarding *Bard’s* filters, is relevant to their warning claim or  
 21 helpful to the jury. *See e.g., Daubert v. Merrell Dow Pharm., Inc.*, 509 U.S. 579, 580  
 22 (1993) (holding that Rule 702 “demand[s] a valid scientific connection to the pertinent  
 23 inquiry as a precondition to admissibility”). Indeed, it is unclear what specific warning the  
 24 Plaintiffs propose should have been added regarding the efficacy of IVC filters,  
 25 particularly since the FDA assessed the risks and benefits of IVC filters during each  
 26 510(k) review. Moreover, Plaintiffs did not establish that any of the bellwether implanting  
 27 physicians questioned the efficacy of IVC filters.  
 28




Aside from the opinions copying Dr. Kessler that should be excluded, the Doctors do not provide any manufacturer-specific opinions. (June 21, 2017, Deposition of David Garcia, at 44:16 – 46:10, attached as Exhibit B (testifying that the Doctors’ incorporation of Dr. Kessler’s opinions is the only portion that compares different manufacturers’ filters and agreeing that the rest of the general points in the report are “copied and pasted in the Cook [filter litigation] report” and applicable to IVC filters generally)). Indeed, the Doctors do not even opine that all IVC filters are ineffective; only that they are overprescribed. (Mot. Ex. A, Rep., at p. 6 (acknowledging that “[t]he existing literature supports the use of vena cava filters in one setting: acute venous thromboembolism with a contraindication to anticoagulation”).) As a result, all of the Doctors’ physician expectations opinions should be excluded. *See e.g., Johnson v. Wyeth LLC*, No. CV 10-02690-PHX-FJM, 2012 WL 1150857, at \*3 (D. Ariz. Apr. 5, 2012) (“[P]laintiff has not presented any evidence suggesting that [the prescribing physician] was ever exposed to Wyeth’s marketing efforts. Without a link between Wyeth’s marketing and plaintiff’s prescribing doctor, Dr. Hollon’s opinions about the subtle effects of marketing on prescribing practices are irrelevant.”); *In re Gadolinium-Based Contrast Agents Prod. Liab. Litig.*, No. 1:08 GD 50000, 2010 WL 5173568, at \*6 (N.D. Ohio June 18, 2010), *aff’d sub nom. Decker v. GE Healthcare Inc.*, 770 F.3d 378 (6th Cir. 2014) (“A generic expert testifying at length about how NSF is diagnosed and how other conditions, such as diabetes, complicates NSF diagnosis is not relevant unless the particular plaintiff has diabetes and a case-specific expert testifies that the plaintiff does not have NSF. In that case, the generic expert’s testimony would be superfluous.”).

**C. Dr. Garcia Did Not Use Reliable Methodology or Analysis for Jones-Specific Opinions.**

Plaintiffs concede that Dr. Garcia based his opinion on his observations of *whole* IVC filters promoting thrombosis (Pl. Br. at 9), but do not address Bard’s argument that Dr. Garcia provides no basis or methodology to extrapolate an entire filter causing thrombosis to a single strut fragment causing thrombosis. “District court judges are to

consider not only (1) whether the method has gained general acceptance in the relevant scientific community, but also (2) whether the method has been peer-reviewed, (3) whether the method ‘can be (and has been) tested,’ and (4) whether there is a ‘known or potential rate of error.’” *Lust By & Through Lust v. Merrell Dow Pharm., Inc.*, 89 F.3d 594, 597 (9th Cir. 1996) (citation omitted). The fractured strut in Plaintiff Jones’ case is less than nine percent of the material of a whole filter (the Eclipse has 12 struts total), is a different shape than a whole filter, and is located in a different artery of the body with different blood flow.



Plaintiffs cannot argue this opinion is reliable based on Dr. Garcia’s experience when Dr. Garcia has never seen a thrombus caused by a filter strut in his personal experience or in the medical literature. (Mot. Ex. D, Garcia Dep. at 225:24 – 228:14.) Moreover, he “do[es] [no]t have any evidence” that the size of the foreign body affects whether it will cause thrombosis. (*Id.*) In other words, Dr. Garcia provides no scientific basis that a single strut of a filter can cause thrombosis. This is precisely the type of “junk science” that *Daubert* and Rule 702 were designed to keep from reaching a jury. *Kennedy v. Collagen Corp.*, 161 F.3d 1226, 1229 (9th Cir. 1998) (“To claim that such inert [collagen medical device] objects may cause lupus surely would be ‘junk science.’”); *cf. Messick v. Novartis Pharm. Corp.*, 747 F.3d 1193, 1199 (9th Cir. 2014) (“While the district court must act as a gatekeeper to exclude ‘junk science’ under *Daubert*, Federal Rule of Evidence 702(a)

1 includes within its scope all evidence that would ‘help the trier of fact ... to determine a  
2 fact in issue.’ A doctor using a differential diagnosis grounded in significant clinical  
3 experience and examination of medical records and literature can certainly aid the trier of  
4 fact and cannot be considered to be offering ‘junk science.’”). Finally, this opinion that a  
5 single strut can promote thrombosis is another generic IVC filter opinion that is unhelpful  
6 due to its lack of specificity to Bard’s IVC filters (and inappropriate for a “case-specific”  
7 opinion).

8 Lastly, Bard argued that Dr. Garcia’s opinion that Plaintiff Jones should be  
9 anticoagulated should be excluded because he did not have an understanding of her  
10 medical condition, did not recall any of the relevant facts of her medical history during his  
11 deposition, and could not testify one way or the other, contrary to his report, that Plaintiff  
12 Jones should receive anticoagulation. Plaintiffs’ response is merely that differing medical  
13 opinions should be submitted to the jury. (Pl. Br. at 10-11.) However, this is not an issue  
14 of differing medical opinions. This is an issue of Dr. Garcia’s failure to reliably review  
15 Plaintiff Jones’ medical records and prepare a methodologically sound treatment plan. Dr.  
16 Garcia admitted that “active GI bleeding would be a reason you – that one has to withhold  
17 anticoagulation, at least until the cause of the bleeding is sorted out and it’s treated,” but  
18 he did not “remember the specific outcome” in Plaintiff Jones’ case. (Mot. Ex. D, Garcia  
19 Dep. at 222:14 – 223:3.) Even Plaintiff Jones’ other medical expert, Dr. Muehrcke,  
20 admitted that Plaintiff Jones is contraindicated and cannot be given anticoagulation. (July  
21 24, 2017, Deposition of Derek Muehrcke, at 136:20-23, attached as Exhibit C.) All other  
22 experts are in agreement, besides Dr. Garcia who could not recall Plaintiff Jones’ medical  
23 history, that Plaintiff Jones is contraindicated for anticoagulation. As a result, all of Dr.  
24 Garcia’s case-specific opinions should be excluded.

## 25 CONCLUSION

26 The Doctors’ opinions based on their brief review of Dr. Kessler’s report, including  
27 their opinions regarding physician expectations, are not only inadmissible under Rule 702,  
28 but are also unhelpful and unreliable under *Daubert*. And, Dr. Garcia’s opinions in

1 Plaintiff Jones' case lack any scientific support or methodology. Accordingly, these  
2 opinions should be excluded in their entirety.

3 DATED this 18th day of October, 2017.

4 s/Richard B. North, Jr.  
5 Richard B. North, Jr.  
6 Georgia Bar No. 545599  
7 Matthew B. Lerner  
8 Georgia Bar No. 446986  
9 NELSON MULLINS RILEY & SCARBOROUGH, LLP  
10 Atlantic Station  
11 201 17th Street, NW / Suite 1700  
12 Atlanta, GA 30363  
13 PH: (404) 322-6000  
14 FX: (404) 322-6050  
15 richard.north@nelsonmullins.com  
16 matthew.lerner@nelsonmullins.com

11 James R. Condo (#005867)  
12 Amanda Sheridan (#005867)  
13 SNELL & WILMER L.L.P.  
14 One Arizona Center  
15 400 E. Van Buren  
16 Phoenix, AZ 85004-2204  
17 PH: (602) 382-6000  
18 JCondo@swlaw.com  
19 ASheridan@swlaw.com

20 **Attorneys for Defendants C. R. Bard, Inc. and**  
21 **Bard Peripheral Vascular, Inc.**

**CERTIFICATE OF SERVICE**

I hereby certify that October 18, 2017, the foregoing was electronically filed with the Clerk of Court using the CM/ECF system which will automatically send e-mail notification of such filing to all attorneys of record.

s/Richard B. North, Jr.  
Richard B. North, Jr.